Apolipoprotein E Polymorphism in Hemodialyzed Patients and Healthy Controls

Abstract

The possible association between the end-stage renal disease (ESRD) and apolipoprotein E (APOE) polymorphism was found in some, but not all studies. We have analysed the APOE genotypes in 995 haemodialysed patients (cases) and a sample of 6242 healthy individuals (controls) in the Czech Republic. There was a statistically significant difference in the frequencies of APOE alleles between the cases and controls, with more carriers of the APOE2 allele in ESRD patients (15.9%) than in controls (12.2%) (p=0.005). The odds ratio of ESRD for the APOE2 allele, compared with APOE3E3 homozygotes, was 1.37 (95% confidence interval 1.13-1.67). The strength of the association increased with the time spent on haemodialysis: the odds ratios of all-cause ESRD in patients dialysed for 8 or more years, 1-8 years and less than one year (non-survivors) were 1.27 (0.94-1.71), 1.41 (1.09-1.81) and 1.94 (0.88-4.18), respectively. This study suggests that the APOE2 allele is a possible genetic risk factor for all-cause ESRD in Caucasians.

Distribution and effect of APO E genotype on plasma lipid in non-obese and obese in north Indian population

“…18 The effect of the APOE polymorphism on the TC/HDL-C and apo A-I/apo B ratios is modulated by BMI z-score and adiponectin levels. 19 23,24 This is consistent with our present results. A mechanism may account for the association of the E4 allele with hypercholesterolemia (e.g., increased LDL-C).…”

Association of apolipoprotein E gene polymorphism with end-stage renal disease and hyperlipidemia in patients on long-term hemodialysis

“…12, 13 Hubacek et al reported in a large population of Caucasians ESRD patients an association between apoe2 allele and all-cause ESRD especially in oneyear non-survivors. 14 However, most studies in renal disease patients showed no significant difference in both allele and genotype frequencies between the patients and healthy subjects. [15][16][17][18] It was recently suggested that the e4 allele has an independent negative impact on renal patient and graft survival in the long term, particularly in older patients.…”

The Association Between SerumApoEGenetic Polymorphism and Serum Lipid Level in Hemodialysis Patients

“…Growing evidence indicates that apolipoprotein E (ApoE) is one of the most important candidate genes contributing to the need for HD, and the single-nucleotide polymorphisms in the ApoE gene could influence the expression and function of ApoE proteins, thus contributing to the risk of HD, and affecting the prognosis of HD patients (Olmer et al, 1997;Kohlmeier et al, 1998;Imura et al, 1999;Guz et al, 2000;Zahalkova et al, 2002;Asakimori et al, 2003;Liberopoulos and Elisaf, 2003;Wang et al, 2003;Liberopoulos et al, 2004;Arikan et al, 2007;Al-Muhanna et al, 2008;Hubacek et al, 2009;Chmielewski et al, 2010Chmielewski et al, , 2011. Several ApoE genetic polymorphisms e2, e3, and e4, coding for the three main isoforms of the ApoE protein E2 (Arg158Cys), E3 (parent isoform), and E4 (Cys112Arg), have been investigated for potential associations with serum lipid levels in HD, and the risk of HD in different populations (Imura et al, 1999;Guz et al, 2000;Wang et al, 2003;Liberopoulos et al, 2004;Arikan et al, 2007).…”